Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
HOME > REGULATORY
REGULATORY
- FY2014 NHI Price Revision Down 5.7% Excluding Tax Adjustments
December 24, 2013
- MHLW Will Level Charges against Novartis, If Necessary: Minister
December 24, 2013
- Premium for Innovativeness or Usefulness (I) Set as Prerequisite for 10% “Precursor Premium”
December 20, 2013
- Generic Share Fails to Meet FY2012 Target but Reaches 47% in New Calculation Method
December 20, 2013
- Chuikyo’s DPC Subcommittee Continues to Support Original Proposal on Generic Drug Index; Will Report Accordingly at Upcoming General Meeting
December 20, 2013
- PhRMA Japan Head, Other Observers Invited for Comments for First Time at Health Ministry Vaccination Panel
December 20, 2013
- Vaccine Dose Intervals to Become More Flexible Starting Next April
December 20, 2013
- Plan to “Institutionalize” Key Premium Ditched for FY2014 Revision; Status Quo to Remain
December 19, 2013
- Chuikyo Subcommittee Agrees on 60% Rule for First Generic Prices, 70% for Biosimilars
December 19, 2013
- Off-Patent Drugs to Get Continuous Price Cuts Until 60% Generic Share Reached
December 19, 2013
- “COI Management” to Be Specified in Unified Ethics Code for Epidemiological, Clinical Research
December 18, 2013
- Japan NIH to Be Staffed with 100-Plus Employees from 6 Govt Organizations
December 18, 2013
- MHLW Boots Up Project Team to Spur Clinical Application of Novel Drugs; Paper Due Out in April
December 17, 2013
- Japan Govt OKs Basic Policy for FY2014 Budget; Wording Tweaked in Favor of Healthcare Circles
December 17, 2013
- Diovan Panel to Reopen Discussions on Dec. 25, Hear from 3 Universities
December 17, 2013
- Amount of Funding from Pharma Companies to Healthcare Professionals Totals 466.6 Billion Yen in FY2012
December 17, 2013
- Bill Payers at Chuikyo Oppose Proposal on Evaluation of Generic Drug Use at DPC Hospitals; Subcommittee to Meet Again on Dec. 18
December 16, 2013
- First Generics of Livalo, Glivec Added to NHI Price List: MHLW
December 13, 2013
- No Diovan, Livalo AGs for December Generic NHI Listing
December 13, 2013
- PFSB Begins Discussions Toward Lifting Ban on Subcontracting of Safety Management Tasks
December 12, 2013
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…